TABLE 3.
The specifications of the ELISA tests.
| ELISA | Detection limit (pM) | Sensitivity** | Intra-assay CV % | Inter-assay CV% |
| C1-INHt | 5.9 | 1.8 × 10–6 | 6.0 | 8.0 |
| C1-INHa | 80 | 3.5 × 10–5 | 5.7 | 12.1 |
| C1r/C1-INH | 1.5 | 1.4 × 10–4 | 17.5 | 17.4 |
| C1s/C1-INH | 3.0 | 5.0 × 10–4 | 11.2 | 19.3 |
| MASP-1/C1-INH | 0.27 | 2.9 × 10–4 | 8.1 | 15.5 |
| MASP-2/C1-INH | 5.8 | 8.6 × 10–2 | 16.1 | 11.1 |
| Kallikrein/C1-INH | 8.1 | 1.6 × 10–5 | 7.9 | 9.1 |
| FXIIa/C1-INH | 2.1 | 5.5 × 10–4 | 7.5 | 9.0 |
| FXIa/C1-INH | 0.5 | 7.4 × 10–3 | 11.2 | 14.9 |
| Thrombin/C1-INH* | 1.2 | 6.0 × 10–5 | 10.9 | 19.5 |
C1-INHt: total C1-INH concentration. C1-INHa: active C1-INH concentration. *Thrombin was incubated in the presence of 2 U/ml heparin, with an 8-fold excess of C1-INH. **The detection limit of the ELISA (pM) is divided by the plasma concentration of C1-INHt or C1-INHa or zymogen, respectively (see Table 2, converted into pM). C1r, C1s: recombinant, in-house (33); MASP-1, MASP-2: recombinant, in-house (34); kallikrein, FXIIa, FXIa: Innovative Research; thrombin: Merck.